Cardiovascular system

Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

3 weeks ago talkbio0Tagged Cardiovascular system, Diabetes Mellitus, Non-Insulin-Dependent, dulaglutide, eli lilly, expansion, Hemoglobin A1c measurement, MACE-3, Mortality Vital Statistics, Mounjaro, non-inferiority, outcomes, SURPASS-CVOT, Trulicity, United States Food and Drug Administration, Weight Loss

Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion

Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

3 months ago talkbio0Tagged Cardiovascular system, heart drug, Inflammation, interleukin-6, Markers (device), Nordisk, pacibekitug, Phase 2 trial, SMPX gene, tourmaline, United States Food and Drug Administration

Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6

Heartbeat Chronicles: Inspiring Stories and Breakthroughs in Cardiovascular Health

6 months ago talkbio0Tagged cardiac research, Cardiovascular system, Heart Diseases, heart health, medical advancements

Heart disease, patient stories, medical advancements, cardiac research, heart health, cardiovascular breakthroughs

Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication

7 months ago talkbio0Tagged Cardiovascular system, Discontinuation (procedure), Gout, Risk, scrutiny, Takeda, Uloric, United States Food and Drug Administration

Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

9 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

9 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

9 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

10 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment

12 months ago talkbio0Tagged Cardiovascular system, China, etripamil nasal spray, Milestone, Paroxysmal, Paroxysmal supraventricular tachycardia, Pharmaceuticals Ltd, Regulatory Filing, Tenascin, human

Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies

Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients

12 months ago talkbio0Tagged Bayer, Cardiovascular system, FINEARTS-HF, Heart failure, Kerendia, KIAA0753 gene, Phase 3 Clinical Trials

Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER